Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Denton

Showing results (501-510 of 535) with videos related to

Pageof 54
Sort By:
Annals of the Rheumatic Diseases|April 18, 2020
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trialDinesh Khanna, Yannick Allanore, Christopher P Denton, et al.
Rheumatology (Oxford, England)|March 9, 2024
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosisDinesh Khanna, Frank Kramer, Josef Höfler, et al.
Annals of the Rheumatic Diseases|May 30, 2026
Novel HLA class I and II insights into the pathogenesis of systemic sclerosis-associated interstitial lung diseaseCarlos Rosa-Baez, Carlos Rangel-Peláez, Inmaculada Rodriguez-Martin, et al.
Rheumatology (Oxford, England)|September 10, 2024
The 2024 British Society for Rheumatology guideline for management of systemic sclerosis-executive summaryChristopher P Denton, Enrico De Lorenzis, Elen Roblin, et al.
Rheumatology (Oxford, England)|September 10, 2024
The 2024 British Society for Rheumatology guideline for management of systemic sclerosisChristopher P Denton, Enrico De Lorenzis, Elen Roblin, et al.
Arthritis Care & Research|June 15, 2026
Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study from the EUSTAR CohortStefano Di Donato, Marie-Elise Truchetet, Marco Minerba, et al.
Annals of the Rheumatic Diseases|September 5, 2015
Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathwayElena López-Isac, Diana Campillo-Davo, Lara Bossini-Castillo, et al.
Rheumatology (Oxford, England)|January 29, 2025
A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysisHilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
Rheumatology (Oxford, England)|February 13, 2021
The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohortMaria-Grazia Lazzaroni, Emiliano Marasco, Corrado Campochiaro, et al.
Pageof 54

Showing results (501-510 of 535) with videos related to

Sort By:
Pageof 54
Annals of the Rheumatic Diseases|April 18, 2020
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trialDinesh Khanna, Yannick Allanore, Christopher P Denton, et al.
Rheumatology (Oxford, England)|March 9, 2024
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosisDinesh Khanna, Frank Kramer, Josef Höfler, et al.
Annals of the Rheumatic Diseases|May 30, 2026
Novel HLA class I and II insights into the pathogenesis of systemic sclerosis-associated interstitial lung diseaseCarlos Rosa-Baez, Carlos Rangel-Peláez, Inmaculada Rodriguez-Martin, et al.
Rheumatology (Oxford, England)|September 10, 2024
The 2024 British Society for Rheumatology guideline for management of systemic sclerosis-executive summaryChristopher P Denton, Enrico De Lorenzis, Elen Roblin, et al.
Rheumatology (Oxford, England)|September 10, 2024
The 2024 British Society for Rheumatology guideline for management of systemic sclerosisChristopher P Denton, Enrico De Lorenzis, Elen Roblin, et al.
Arthritis Care & Research|June 15, 2026
Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study from the EUSTAR CohortStefano Di Donato, Marie-Elise Truchetet, Marco Minerba, et al.
Annals of the Rheumatic Diseases|September 5, 2015
Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathwayElena López-Isac, Diana Campillo-Davo, Lara Bossini-Castillo, et al.
Rheumatology (Oxford, England)|January 29, 2025
A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysisHilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
Rheumatology (Oxford, England)|February 13, 2021
The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohortMaria-Grazia Lazzaroni, Emiliano Marasco, Corrado Campochiaro, et al.
Pageof 54